secwatch.observer — SEC 8-K summary
======================================

Issuer:     Processa Pharmaceuticals, Inc. (PCSA)
CIK:        0001533743
Form:       8-K
Filed at:   2022-07-25T23:59:59+00:00
Accession:  0001493152-22-020258
Event type: leadership
Sentiment:  neutral
Materiality: 0.35
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Processa appoints James R. Neal, CEO of XOMA, to board of directors
-------------------------------------------------------------------

- James R. Neal appointed to Processa Board effective July 19, 2022.
- Neal is CEO and Chairman of XOMA; also on board of Palisade Bio and Monterey Bio Acquisition.
- Appointment brings life sciences and public company experience to Processa board.
- Neal will be compensated as per non-employee director program described in May 31, 2022 proxy statement.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1533743/000149315222020258/0001493152-22-020258-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1533743/000149315222020258/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-22-020258

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer